BIOMAT Database Logo BIOMAT Database Logo

Management of beta-thalassemia major using transfusions and iron chelation with deferoxamine. 1988

M H Freedman
Division of Hematology/Oncology, Hospital for Sick Children, Department of Pediatrics, University of Toronto, Canada.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D001803 Blood Transfusion The introduction of whole blood or blood component directly into the blood stream. (Dorland, 27th ed) Blood Transfusions,Transfusion, Blood,Transfusions, Blood
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013789 Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. Thalassemias
D016913 Blood Component Transfusion The transfer of blood components such as erythrocytes, leukocytes, platelets, and plasma from a donor to a recipient or back to the donor. This process differs from the procedures undertaken in PLASMAPHERESIS and types of CYTAPHERESIS; (PLATELETPHERESIS and LEUKAPHERESIS) where, following the removal of plasma or the specific cell components, the remainder is transfused back to the donor. Blood Component Transfusions,Component Transfusion, Blood,Component Transfusions, Blood,Transfusion, Blood Component,Transfusions, Blood Component

Related Publications

M H Freedman
Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.
January 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance,
M H Freedman
Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
April 1978, The Journal of pediatrics,
M H Freedman
Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine.
May 2016, Electronic physician,
M H Freedman
Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
January 2010, Acta haematologica,
M H Freedman
Iron chelation adherence to deferoxamine and deferasirox in thalassemia.
May 2011, American journal of hematology,
M H Freedman
Iron Chelation in Thalassemia Major.
December 2015, Clinical therapeutics,
M H Freedman
Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
January 2008, Hemoglobin,
M H Freedman
Clinical Challenges with Iron Chelation in Beta Thalassemia.
April 2023, Hematology/oncology clinics of North America,
M H Freedman
Early iron chelation therapy in thalassemia major.
January 1983, Haematologica,
M H Freedman
[Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
May 1994, Medicina clinica,
Copied contents to your clipboard!